GLPwatch
Papers (10410)
Page 139 of 174, ranked by citation count.
- Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight/Obesity: A Narrative Review of Efficacy, Safety, and Quality-of-Life Outcomes.
- GLP-1RA Liraglutide Attenuates Sepsis by Modulating Gut Microbiota and Associated Metabolites.
- The Sit Less, Interact and Move More (SLIMM-2) Trial: Protocol for a randomized control trial of a sedentary behavior intervention, resistance training and semaglutide on sedentary behavior in persons with chronic kidney disease.
- Tirzepatide: A Double Agonist for Various People Living with Type 2 Diabetes.
- [Obesity treatment: will pharmacotherapies replace metabolic surgery in the future?]
- Liraglutide Plus Dapagliflozin for High Uric Acid and Microalbuminuria in Diabetes Mellitus Complicated With Metabolic Syndrome.
- Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review.
- Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes.
- GLP-1 agonist-associated presentations to unscheduled care: An opportunistic pilot study.
- SOUL searching in GLP-1 therapy: Oral semaglutide confirms cardioprotection in type 2 diabetes.
- Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
- Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
- Once-Weekly Semaglutide Is an Effective Adjunct for Weight Loss in Adults without Diabetes Who Are Overweight or Obese.
- [Pharmacological profile and clinical trial results of a long-acting, once weekly human GLP-1 receptor agonist Dulaglutide (Genetical Recombination)].
- Liraglutide (Saxenda) for weight loss.
- New drugs: dulaglutide, olodaterol hydrochloride, and vorapaxar sulfate.
- Efficacy of newer agents in the glycaemic management of patients with type 2 diabetes.
- Great Expectations: Semaglutide as Antidiabetic Weight Management in a Psychiatric Hospital.
- Clinical Manifestations of Semaglutide Overdose: A Case Study.
- Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.
- Tirzepatide vs. Semaglutide for Obesity Treatment.
- Decreased complexity of glucose dynamics in diabetes in rhesus monkeys.
- Incretins (GLP-1 Receptor Agonists) and Polycystic Ovaries.
- Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.
- Treatment satisfaction and time in range after 16 weeks of treatment with iGlarLixi in insulin-naive adults with suboptimally controlled type 2 diabetes.
- Discontinuation of Tirzepatide and Semaglutide Prior to Gastric Sleeve Surgery: Clinical Considerations and Guidelines.
- Exploring Dietary Intake in Adults with Type 2 Diabetes Using GLP-1 Receptor Agonists: A Cross-Sectional Analysis.
- Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial.
- Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes.
- The effects of liraglutide and metformin treatment on fracture healing in partially insulinopenic diabetic rats.
- Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis.
- Do GLP-1 Receptor Agonists Care if You Have Heart Failure?
- Semaglutide and tirzepatide in prediabetes: Evidence for diabetes prevention and cardiovascular protection.
- Short-term effects of liraglutide and semaglutide on weight gain and adiposity by rats fed a Western diet.
- Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes.
- Impact of oral semaglutide on serum urate levels in people with type 2 diabetes: A retrospective real-world analysis (URISEMA study).
- [Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors and the cardiovascular system].
- Response to the comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 trials".
- Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population.
- Erratum. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37:2159-2167.
- Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies.
- Lilly's tirzepatide and Novo Nordisk's semaglutide vie for top drug spot.
- Tirzepatide vs. Semaglutide for Obesity Treatment.
- Improvement of Chronic Spontaneous Urticaria After Glucagon-Like Peptide 1 Receptor Agonist Therapy: Report of Two Cases.
- The role of glucagon-like peptide-1 receptor agonists in cardiovascular disease prevention in type 2 diabetes mellitus: evidence from the most recent clinical trials.
- Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus.
- Beyond Glycemic Control: Concurrent GLP-1 Receptor Agonist Use Is Associated with Reduced Urinary Adverse Events Following OnabotulinumtoxinA Treatment in Non-Diabetic Adults with Overactive Bladder.
- PRISMA-efficacy and safety of lixisenatide for type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
- Dual-sensitive gelatin-coated chitosan microparticles for targeted semaglutide pulmonary delivery: a novel approach to enhancing anti-inflammatory and anti-fibrotic effects.
- Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management.
- Dulaglutide markedly prevents peritoneal fibrosis in a rodent model of chronic kidney disease: Insights into the pathogenesis.
- Tirzepatide Outperforms Semaglutide in Head-to-Head Obesity Trial.
- Treatment of obesity-related HFpEF: a STEP closer to the SUMMIT.
- [An orally administered glucagon-like peptide 1 (GLP1) analogue: A landmark in the treatment of type 2 diabetes].
- A pre-specified analysis of the SELECT trial suggests a kidney benefit of semaglutide in patients without diabetes.
- Liraglutide Ameliorates Methotrexate-Induced Cardiotoxicity in Rats: Modulation of Oxidative Stress, Autophagy, and the TNF-α/NF-κB Signaling Inflammatory Pathway.
- Dulaglutide slows kidney disease in type 2 diabetes.
- Incretin physiology and its role in type 2 diabetes mellitus.
- The Role of Race and Ethnicity in the Response to Metabolic Dysfunction-Associated Steatotic Liver Disease Treatment: A Review.
- Neuroprotective Effects of Liraglutide and/or Rivastigmine Combination on the Rat Hippocampus.